Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies
出版年份 2014 全文链接
标题
Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 23, Issue 8, Pages 1055-1066
出版商
Informa Healthcare
发表日期
2014-07-07
DOI
10.1517/13543784.2014.918952
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition
- (2014) William T. Cefalu JOURNAL OF CLINICAL INVESTIGATION
- The New Weight-Loss Drugs, Lorcaserin and Phentermine-Topiramate
- (2014) Steven Woloshin et al. JAMA Internal Medicine
- Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity
- (2013) Manuel de Lera Ruiz et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Melanocortin 4 Receptors Reciprocally Regulate Sympathetic and Parasympathetic Preganglionic Neurons
- (2013) Jong-Woo Sohn et al. CELL
- Microsomal transfer protein inhibition in humans
- (2013) Marina Cuchel et al. CURRENT OPINION IN LIPIDOLOGY
- Long-term Drug Treatment for Obesity
- (2013) Susan Z. Yanovski et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice
- (2013) Shannon M Reilly et al. NATURE MEDICINE
- Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus
- (2013) Harold E. Bays et al. Obesity
- Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults
- (2013) Louis J. Aronne et al. Obesity
- A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)
- (2013) Caroline M. Apovian et al. Obesity
- First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus
- (2013) Anita Kapur et al. BMC Pharmacology & Toxicology
- Chronic Treatment With a Melanocortin-4 Receptor Agonist Causes Weight Loss, Reduces Insulin Resistance, and Improves Cardiovascular Function in Diet-Induced Obese Rhesus Macaques
- (2012) P. Kievit et al. DIABETES
- A review of late-stage CNS drug candidates for the treatment of obesity
- (2012) D J Heal et al. INTERNATIONAL JOURNAL OF OBESITY
- Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons
- (2012) Marcelo O. Dietrich et al. NATURE REVIEWS DRUG DISCOVERY
- Melanocortin-4 Receptors Expressed by Cholinergic Neurons Regulate Energy Balance and Glucose Homeostasis
- (2011) Jari Rossi et al. Cell Metabolism
- JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, ameliorates impaired glucose and lipid metabolism in Zucker diabetic fatty rats
- (2011) T. Hata et al. DIABETES OBESITY & METABOLISM
- Novel strategy for the use of leptin for obesity therapy
- (2011) Charmaine S Tam et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- A Small-Molecule Inhibitor of Enterocytic Microsomal Triglyceride Transfer Protein, SLx-4090: Biochemical, Pharmacodynamic, Pharmacokinetic, and Safety Profile
- (2011) E. Kim et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Central and Peripheral Molecular Targets for Antiobesity Pharmacotherapy
- (2010) M A Valentino et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs
- (2010) Pradeep J. Nathan et al. CNS Neuroscience & Therapeutics
- Histamine H3Receptor as a Drug Discovery Target
- (2010) Michael Berlin et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Histamine H3 Receptor and Eating Behavior
- (2010) M. B. Passani et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Current and Future Drug Targets in Weight Management
- (2010) Renger F. Witkamp PHARMACEUTICAL RESEARCH
- Reward, dopamine and the control of food intake: implications for obesity
- (2010) Nora D. Volkow et al. TRENDS IN COGNITIVE SCIENCES
- Results of Roux-en-Y Gastric Bypass in Morbidly Obese vs Superobese Patients
- (2009) Michel Suter ARCHIVES OF SURGERY
- Stimulation of Cholecystokinin-A Receptors With Gl181771X: A Failed Clinical Trial That Did Not Test the Pharmacogenetic Hypothesis for Reduction of Food Intake
- (2009) AD Roses CLINICAL PHARMACOLOGY & THERAPEUTICS
- Potent and Selective Agonism of the Melanocortin Receptor 4 With MK-0493 Does Not Induce Weight Loss in Obese Human Subjects: Energy Intake Predicts Lack of Weight Loss Efficacy
- (2009) R Krishna et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Annual Medical Spending Attributable To Obesity: Payer-And Service-Specific Estimates
- (2009) Eric A. Finkelstein et al. HEALTH AFFAIRS
- Y2 receptor gene variants reduce the risk of hypertension in obese children and adolescents
- (2009) Nicola Santoro et al. JOURNAL OF HYPERTENSION
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity Pharmacotherapy
- (2009) Eric Ravussin et al. Obesity
- Weight Loss, HbA1cReduction, and Tolerability of Cetilistat in a Randomized, Placebo-controlled Phase 2 Trial in Obese Diabetics: Comparison With Orlistat (Xenical)
- (2009) Peter Kopelman et al. Obesity
- Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models
- (2008) Y. Fujimori et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Modulation of Blood Pressure by Central Melanocortinergic Pathways
- (2008) Jerry R. Greenfield et al. NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started